Senesco’s SNS01 is a Potent Regulator of Programmed Cell Death and Tumor Growth in Murine Models of Multiple Myeloma
May 23 2012 - 8:30AM
Business Wire
Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE
MKT: SNT), announced today that the characteristics and activity of
SNS01 have been released on-line in Molecular Therapy, the official
journal of the American Society for Gene & Cell Therapy. The
print version of the article is scheduled to be published during
the summer.
http://www.nature.com/mt/journal/vaop/ncurrent/full/mt201294a.html
“SNS01 is an earlier formulation of Senesco’s therapeutic
candidate SNS01-T, which is currently being evaluated in a Phase
1b/2a clinical study to treat patients with relapsed or refractory
multiple myeloma,” said Leslie J. Browne, Ph.D., President and CEO
of Senesco. “SNS01 helped us to establish the benefits of
modulating the eIF5A pathway to selectively trigger programmed cell
death in malignant B-cells and to develop a more potent and better
tolerated version to take into clinical trials.”
The Company recently announced the oral presentation, entitled
“SNS01-T, an eIF5A-Based Gene Therapy Nanoparticle Designed for the
Treatment of Multiple Myeloma, has Anti-Tumoral Activity in
Lymphoma”, which described the effectiveness of SNS01-T in B-cell
cancers. Research for both publications was performed in Senesco
CSO John Thompson’s research laboratory at the University of
Waterloo in Ontario, Canada.
About SNS01-T
SNS01-T is a novel approach to cancer therapy that is designed
to selectively trigger apoptosis in B-cell cancers such as multiple
myeloma, and, mantle cell and diffuse large B-cell lymphomas.
Senesco is the sponsor of a Phase 1b/2a open-label, multiple-dose,
dose-escalation study which will evaluate the safety and
tolerability of SNS01-T when administered by intravenous infusion
to relapsed or refractory multiple myeloma patients. The study is
actively enrolling patients at the Mayo Clinic in Rochester, MN,
the University of Arkansas for Medical Sciences in Little Rock, and
the Mary Babb Randolph Cancer Center in Morgantown, West Virginia.
http://www.clinicaltrials.gov/ct2/show/NCT01435720?term=SNS01-T&rank=1
About Multiple Myeloma
Multiple myeloma is an incurable cancer of plasma cells, a type
of white blood cell derived from B-lymphocytes, normally
responsible for the production of antibodies, in which abnormal
cells accumulate in the bone marrow leading to bone lesions and
interfering with the production of normal blood cells. Senesco was
previously granted orphan drug status for SNS01-T, the Company’s
lead drug candidate for treatment of multiple myeloma.
About Senesco Technologies, Inc.
Senesco, a leader in eIF5A technology, is running a clinical
study in multiple myeloma with its lead therapeutic candidate
SNS01-T, which targets B-cell cancers by selectively inducing
apoptosis by modulating eukaryotic, translation, initiation Factor
5A (eIF5A), which is believed to be an important regulator of cell
growth and cell death. Accelerating apoptosis may have applications
in treating cancer, while delaying apoptosis may have applications
in treating certain inflammatory and ischemic diseases. Senesco has
already partnered with leading-edge companies engaged in
agricultural biotechnology and is entitled to earn research and
development milestones and royalties if its gene-regulating
platform technology is incorporated into its partners’
products.
Forward-Looking Statements
Certain statements included in this press release are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results could
differ materially from such statements expressed or implied herein
as a result of a variety of factors, including, but not limited to:
the ability of the Company to consummate additional financings; the
Company’s ability to recruit and enroll patients in its clinical
trial; the development of the Company’s gene technology; the
approval of the Company’s patent applications; the successful
implementation of the Company’s research and development programs
and collaborations; the success of the Company's license
agreements; the acceptance by the market of the Company’s products;
the timing and success of the Company’s preliminary studies,
preclinical research and clinical trials; competition and the
timing of projects and trends in future operating performance, the
Company’s ability to comply with the continued listing standards of
the NYSE Amex, as well as other factors expressed from time to time
in the Company’s periodic filings with the Securities and Exchange
Commission (the "SEC"). As a result, this press release should be
read in conjunction with the Company’s periodic filings with the
SEC. The forward-looking statements contained herein are made only
as of the date of this press release, and the Company undertakes no
obligation to publicly update such forward-looking statements to
reflect subsequent events or circumstances.
Senesco (AMEX:SNT)
Historical Stock Chart
From Oct 2024 to Nov 2024
Senesco (AMEX:SNT)
Historical Stock Chart
From Nov 2023 to Nov 2024
